September 26, 2021 Via Email (mohantyadi@gmail.com) Mr. Aditya Mohanty Chief Executive Officer EnCellx, Inc.

Exhibit 99.3

 

September 26, 2021

Via Email (xxxxxxxxxx@xxxxx.xxx)

Xx. Xxxxxx Xxxxxxx

Chief Executive Officer

EnCellx, Inc.

000 Xxxxxx Xxxxx Xxxxx, Xxxx xx Xxxxxxxxxx,

Xxxxxxx of Xxx Xxxxxx, 00000, Xxxxxxxx

Re: Amended and Restated Share Transfer Agreement (this “STA”) made and entered into by and between EnCellX, Inc., a Delaware corporation and Cellect Biotechnology Ltd., an Israeli company

Dear Adi:

This letter sets forth our agreement to amend the STA, as we discussed. Effective as of the date hereof, Section 3.01 of the STA shall be replaced with the following Section 3.01:

The closing (the “Closing”) of the purchase and sale of the Shares hereunder shall be held concurrently with the closing of the merger agreement between the Seller and Quoin Pharmaceuticals, Inc. to which this Agreement is attached as an exhibit (the “Merger Agreement”), but in any event no later than November 1, 2021.

In all other respects, the provisions of the STA shall remain in full force and effect.

Please sign below to confirm your agreement to this amendment.

Sincerely,

Xxxx Xxxxxxx

CEO

CELLECT BIOTECHNOLOGY, LTD.
By:	/s/ Xxxx Xxxxxxx CEO
	Xxxx Xxxxxxx CEO
EnCellx, INC.
By:	/s/ Xxxxxx Xxxxxxx
	Xxxxxx Xxxxxxx
	CEO